Corrects total revenue to $54.34 mln, from $51.7 mln, and removes comparison with estimates in Overview and Key Details sections
Overview
Liquidia posts Q3 total revenue of $54.34 mln
Company achieves operating profitability in first full quarter of YUTREPIA sales
Posts net loss; adjusted loss/share beats consensus
Outlook
Liquidia plans to advance L606 into pivotal trials
Company aims for sustained growth and profitability
Liquidia sees YUTREPIA as a potential preferred treatment
Result Drivers
YUTREPIA LAUNCH - Strong sales of YUTREPIA, with $51.7 mln in net product sales as launch momentum continues
PRESCRIPTION GROWTH - Over 2,000 unique prescriptions and 1,500 patient starts contributed to sales momentum, as of Oct 30
COST MANAGEMENT - Positive operating income and adjusted EBITDA reflect effective cost management alongside revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 TOTAL REVENUE | $54.34 mln | ||
Q3 EPS | Beat | -$0.04 | -$0.40 (9 Analysts) |
Q3 NET INCOME | -$3.53 mln | ||
Q3 Operating Income | $1.77 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Liquidia Corp is $37.00, about 34.2% above its October 31 closing price of $24.36
Press Release: ID:nGNX2FLzbw
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)